Sign in
AKTX Stock Price, Chart, Stats & News
Akari Therapeutics, Plc
Save
Akari Therapeutics, Plc (AKTX) does not currently pay a dividend.
8.92M
Market cap
–
Current P/E
–
Forward P/E
AKTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 6.43% |
ROA | -34.67% |
ROE | -68.21% |
D/E | 0.09x |
Interest coverage ratio | -37.65x |
AKTX valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | 0.00x |
EV multiple | -0.02x |
About
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.
Similar securities
Based on sector and market capitalization
Report issue